TLR2 and influenza: A reduction in influenza-associated secondary pneumococcal infections has been reported in mice co-administered with inhaled TLR2 agonists and inactivated vaccines, highlighting the effectiveness of TLR agonists in influenza vaccines (Hussell and Goenka, 2016).